ALS is a progressive neurodegenerative disease that robs people of the ability to move and leads them to lose their ability to speak — and eventually breathe.

For over a decade, Biogen has been committed to advancing ALS research to provide a deeper understanding of all forms of this devastating disease, which currently impacts an estimated 352,000 people worldwide.

By leveraging established scientific capabilities and embarking on strong R&D collaborations, we’re determined to follow the science to advance a comprehensive, multi-modality ALS portfolio that fosters our long-term leadership in this space.

Biogen conducts clinical trials in ALS related to the investigational therapies in our pipeline to evaluate the efficacy and safety of potential medicines.

View all recruiting Biogen clinical trials in ALS

Deciding to participate in a clinical trial requires careful consideration. In most cases, the therapies investigated in clinical trials are not yet approved by regulatory agencies like the U.S. Food and Drug Administration (FDA). The benefits and risks of taking the treatment are not completely known. By volunteering for a clinical trial, you are helping the medical community determine whether new treatments are safe and effective.

Learn more about clinical trials and access programs